NUVL

Nuvalent is a clinical-stage precision-oncology company developing selective kinase inhibitors, led by zidesamtinib (NVL-520) for ROS1-positive non-small cell lung cancer, with neladalkib and NVL-330 behind it. As a pre-revenue biotech, the financials are pure investment-stage: no revenue, a FY2025 net loss of $425M (operating loss $414M, EPS -$5.85), and operating cash burn of $275M, with the loss driven by clinical-trial, manufacturing and commercial-launch-preparation costs plus R&D expense that rose 41.0% to $307M. Standard valuation lenses (P/E, P/S) are not meaningful here; the negative ratios simply reflect a company funding development ahead of any product sales.

What makes this more than a speculative shell is the clinical and regulatory progress. In June 2025 the company reported positive pivotal data for zidesamtinib in TKI-pretreated ROS1-positive NSCLC, presented the dataset in September 2025, and in November 2025 the FDA accepted the NDA for filing with a PDUFA target action date of September 18, 2026. Zidesamtinib holds Breakthrough Therapy and Orphan Drug designations. This is a de-risked lead asset on the cusp of a first commercial approval, which is a materially better position than most clinical-stage names.